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NASAL DOSAGE FORMS OF PROPRANOL

DETAILED DESCRIPTION
‘

'Thisis a division of application Ser. _No. 63,176, ?led
Aug. 3, 1979, now vU.S. Pat. No. 4,284,648. ‘

‘

THE

INVENTION

The word “propranolol” as used herein is intended to

'

5 encompass/any pharmaceutically acceptable form of
propranolol, i.e., the free base of a pharmaceutically
BACKGROUND OF THE INVENTION
‘acceptable salt or ester thereof. Propranolol, or l-(iso
‘ 1. Field of the Invention
‘
propylamino)-3-(l-naphthyloxy)-2-pr0panol, can be
' The present invention relates to a novel method of
represented
by the structural formula:
administering propranolol, a B-adrenergic-blocking
agent, and to novel dosage forms containing proprano
lol adapted for nasal administration.
'2. Description of‘ the Prior Art

Propranolol, a B-adrenergic-blocking agent, is widely
used therapeutically, chie?y in the management of hy
pertension and in the treatment of angina pectoris, ar-'

rhythmias and other cardiac conditions, and migraine.

The drug is, however, inefficiently and variably ab
sorbed from oral dosage forms. Thus, Shand et al., Clin.
Details of the chemical synthesis ofthe free base, as well
Pharmacol. Therap. 11, 112-120 (1970), report a study in 20 as
a description of pharmaceutically acceptable esters
humans has shown that following Oral administration of

and salts which can be‘ derived therefrom, are set forth
in Crowther et al. US Pat. No. 3,337,628, expressly
incorporated by reference herein and ‘relied upon.
intravenous doses in the same subjects varied only two
fold. Furthermore, the bioavailability of propranolol in 25 According to the present invention, it has been sur
prisingly found that propranolol can be administered
some subjects as calculated from the ratio of the area
nasally with results considerably superior to those ob
under the curve of anI8O mg oral dose and 10 mg I.V.

propranolol, peak plasma levels in ?ve subjects given 80

mg oral doses varied seven fold, while levels for 10 mg

tained with oral administration. The following study

dose was found to be as low as 16%. The variations in

was undertaken to examine the bioavailability of pro
the blood levels as well as the low bioavailability for
oral doses has been attributed by various researchers to 30 pranolol from nasal solution in comparison with the

bioavailability of the drug when administered orally

the extensive metabolism of the drug in the gastrointes
tinal tract during the absorption process and/or to the
effect of the ?rst pass through the liver [Dollery et al.,

and intravenously.

.

'

Sprague Dawley male rats, each weighing ‘about 270

Ann, N. I". Acad. Sci. 179, 109 (1971); ' Suzuki et al.,

grams, were used in this study. For nasal administration,
Chem. Pharm. Bull. 20, 2731 (1972); and Garceau et al., 35 the rats were anesthetized using sodium pentobarbital
JQPharm. Sci. 67, 1360 (1978)].
'
‘
(50 mg/kg) and the drug was administered to the nasal
. cavity by means of a micropipet at dosage levels of l
mg/rat and 2 mg/rat in 0.1 ml of isotonic buffer solution

SUMMARY OF THE INVENTION
In view of the foregoing, it is apparent that a serious

need exists for the improved delivery of propranolol.
Thus, 'it is an object of the present invention to provide

(pH 7.2) according to the procedure described by Hirai
40 et al., the 98th Annual Meeting of Pharmaceutical Soci

ety of Japan, Okayama,April 1978. For intravenous

novel dosage forms and a novel method of administer

administration, the rats were anesthetized and a 1 mg

ing propranolol which will provide enhanced bioavaila

dose of the drug in 0.2 ml isotonic buffer solution (pl-I
bility and minimized variations in blood levels as com
7.2) was injected into each rat through the femoral vein.
pared to oral dosage forms, while at the same time pro 45
After intravenous and nasal administration, blood from
viding relative ease of administration when compared
the femoral aorta was sampled periodically. For oral
to the intravenous route.

administration, the rats .were not anesthetized and 1

The foregoing object,‘ resulting in bioavailability of

mg/rat doses of the drug in 1 ml isotonic buffer solution
(pH
7.2) were administered by means of a stomach tube.
nous administration but without the disadvantages in 50
After oral administration, blood from the tail vein was
herent in that route of administration, is achieved by
sampled periodically. Blood levels of the drug were
nasal administration of propranolol. According to the

propranolol comparable to that achieved by‘intrave~

determined vspectrophotofluorometrically by_ a minor

invention, the propranolol is conveniently administered
via a novel nasal dosage form, i.e., a'solution, ‘suspen
sion, ointment or gel adapted for nasal-administration.

modification of the method of Suzuki et al., Chem.
55

Pharm. Bull. 20, 2731 (1972).

FIG. 1 shows the mean blood levels of propranolol
for the study described above. As seen from FIG. .1, the
blood level of the drug after nasal adminstration of a 1
FIG. i is a semi-logarithmic plot of average blood
mg dose is identical to the blood level after intravenous
levels of propranolol in rats obtained when the drug
was administered via nasal, oral and intravenous routes; 60 administration of a 1 mg dose, whereas oral administra
FIG. 2 is a semi-logarithmic plot of mean plasma
tion at the same dosage level results in considerably
lower blood levels. The oral bioavailabilities calculated
levels of propranolol in dogs after administration of 20
mg doses via nasal, intravenous and oral administration;
from the ratio of the area under the curve (oral

BRIEF DESCRIPTION OF THE'DRAWINGS

and

.

.

.

FIG. 3 isia semi-logarithmic plot of mean bloodlevels
of propranolol inrats after nasal admins‘tration of 1 mg ,
doses, via a nasal solution and via a sustained release
nasal gel.

65

/I.V.)>< 100 and (oral/nasal)><
within 4 hours after
administration were found to be about‘ 15%. Table I
shows the area under the curve (AUC) within 4 hours

after intravenous, nasal and oral administration of pro
pranolol (mg/rat) in rats.

, , V

I
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4
sorbed from the nasalmucosa into systemic blood‘ with

TABLE I '

. out the first pass metabolism. '

AREA UNDER CURVE (AUC) WITHIN 4 HOURS AFTER

Propranolol can be conveniently administered na
sally to warm-blooded animals by formulating it into a

INTRAVENOUS, NASAL AND ORAL‘ ADMINISTRATION
"

'

OF PROPRANOLOL (1 mg) IN RATS‘ "
.

nasal dosage form comprising propranolol and a non

‘ Percentage

AUC04

Route

'

. (ng hr ml* 1)
32.9-

.

.

' Absorbed Compared

mRatio-

to I.V. Route

Intravenous

8072-:

Nasal

804.0 $156.4,

2 0.996 .

.

_~

.

Oral

144.5 : 22.8

0.179

'

>1

.

toxic pharmaceutically acceptable nasal‘. carrier there
for. As indicated earlier, propranolol can be employed
in the form of the free base or in the form of a-pharma

‘

-:99.6%

17.9%

10

‘mean t SE

ceutically acceptablesaltlorester thereof, e. g., propran
olol hydrochloride or. propranolol stearate. Suitable
nontoxic pharmaceutically acceptable nasal carriers
will be apparent to those skilled in the art of nasal phar
maceutical formulations. For those not skilled in the art,
reference is made to the text entitled “REMINGTONZS

It can also be seen from FIG. 1 that the area under the

blood level curve is directly proportional to the dose,
when the drug is administered‘ nasally. Further, it can be
seen that propranolol is very rapidly absorbed from the

PHARMACEUTICAL SCIENCES”, 14th edition,
1970. Obviously, the choice of suitable carriers will
depend on the exact nature of the particular nasal dos‘

nasal mucosa; thus, the peak plasma level is attained
within 5 minutes of the instillation of the nose drops.

age form desired, e.g., whether propranololv is to'; be
The advantages of nasal administration as-compared
to oral administration has also been demonstrated in 20 formulated into a nasal solution (for use as drops or as a
spray), a nasal suspension, a nasal ointment or a nasal
tests in dogs. Details of the test procedure-are set forth
below.

.,

,

.

gel. Preferred nasal dosage forms are solutions and’gels,

‘

which contain' a major amount of water (preferably

Three beagledogs weighing about 10 kg each were
used for this crossover study. For nasal administration,

the dogs were anesthetized _with the intravenous injec
tion of 30 mg/kg of sodium pentobarbital, and 0.2 ml of

25

puri?ed water) in addition to theeactive ingredient.
Minor amounts of other ingredients such as'pH adjust
ers (e.g., a base such as NaOH)‘, buffering agents, preser-'

saline solution containing propranolol hydrochloride

vatives, wetting agents and jelling agents (e.g., methyl-

(20 mg/dog) was theb administered to the nasal cavity

cellulose) may also be present.

'

'

Examples of the preparation of a typical nasal solu- ‘

via a ‘micropipet. For intravenous administration, the

dogs were anesthetizedv and a 20 mg/dog dose of the 30 tion and of a sustained release nasal gel containing pro
drug in 1.0‘ ml saline solution was injected through the
pranolol are set forth below. However, it is to be underi
stood that these examples are given by way ‘of illustra
forelag vein. For oral administration, the dogs were not
tion only and are not to be construed as limiting the
anesthetized and a 20 trig/dog dose of the drug in 50 ml

of water was ‘administered via a stomach tube. After
nasal, intravenous and-‘oral administration, blood was

invention either in spirit or in scope as many modi?ca
35

sampled from the' foreleg ‘vien periodically. Plasma

tions both in materials and in methods will be apparent
to those skilled in the art.

levels of propranolol ‘were determined spectrophoto

‘EXAMPLE 1 '

fluorometrically by a minor‘modi?cation of the method

of Shand et al., CIin. Pharmacql. Therap. 11, 112-120
(1970).

‘

‘

'7

'

"

‘

' 2 Grams of propranolol hydrochloride were dis

solved in 80 ml of distilled water and the pH of the
resultant solution was adjusted to 7.4 with dilute sodium
hydroxide solution. A quantity of water sufficient to
bring the total volume to 100 ml was then added. The
solution was sterilized by being passed through a 0.2

‘

FIG. 2 shows the mean plasma levels of propranolol
for the study described immediately above. As can be
seen from FIG. 2, the plasma levels of the drug after
intravenous and nasal administration are virtually iden

tical, whereas oral'administration results in considera 45 micron Millipore ?lter.
bly lower plasma levels."Table II below summarizes the
EXAMPLE 2
results obtained for each individual dog for the three
routes of administration.

'

'

-

' ‘TABLE II
AREA UNDER PLASMA CURVE WITHIN 8 HOURS

AFTER INTRAVENOUS, NASAL AND ORAL
‘ADMINISTRATION OF PROPRANOLOL (20 mg) IN DOGS
Intra-

venous

Dog

_ (ng hr
ml" 1)

‘

Nasal

'

v "

Oral

‘,(ng hr.’ .(ng hr
1 ml,“ 1) ml" 1)

tant mixture was allowed to stand at room temperature

for 3 hours. Then, 1.84 grams of propranolol stearate
were suspended in 20 grams of water and the suspension
was added to the gel and thoroughly mixed.

.

AUCiNasal!
AUC(I.V.)

A sustained release gel prepared as described'abov
AUC§P.O.! 55
was
nasally administered to rats at the l mg/rat dosage
AUC(I.V.)
level. FIG. 3 shows the mean blood levels of proprano

N106

1702.6

1648.0

151.8 ,

0.967

0.089

1548.1

1538.9

I 93.8 I

0.994

0.059

1.196

1534.9

‘1556.3

117.9 '

1.013

0.076

Mean

1595.2 ‘

1581.0

120.8

0.991

33.7

17.0

0.013

53.8

80 Grams of water were heated to 80° C. and 3.0
grams of Methocel were added, with stirring. The resul

.

I096

SE

50

‘

lol obtained as compared to those obtained'for a- 1mg

0.074

dose of nasal‘ solution. The plot clearly shows that pro
longed release of propranolol can be achieved via‘nasal

0.008

administratiom"

As can be seen’ from Table II supra; the bioavailabil
ity of propranolol from the oral route is only 7.4% of
that of the intravenous route,i'wherelas the bioavailabil
ity from the nasal route is 99.1% that of the intravenous
route. These results ‘and those from the'study, in rats
detailed above indicate that propranolol is rapidly ab

5'

I

i

a

‘v'

EXAMPLE 3
A novel dosage form of an aqueous solution of pro;

pranolol inv a pharmaceutical vehicle and suitable for use
as nasal drops or‘ nasal spray was prepared.‘ The ?nal

compositlo'nfadjusted to pH 7.4, had the following
composition:

F >

'

4,394,390

6

2. The composition as de?ned by claim 1, said com
INGREDIENT

propranolol hydrochloride
Tween 80

position comprising a nasal ointmentl
3. The composition as de?ned in claim ll, said compo
sition comprising a nasal gel.

AMOUNT “

500 mg
2 mg

methyl cellulose

20 mg

water

10 ml.

4. The composition as de?ned by claim 2 or 3,

wherein (i) is a systemically therapeutically effective
unit B-adrenergic block amount of compound having
the formula

Naturally, the therapeutic dosage range for nasal
administration of propranolol according to the present
invention will vary with the size of the patient and the
condition for which the drug is administered. A typical
dose of propranolol would be 10 to 100 mg adminis

tered nasally three times daily. The quantity of nasal 15
dosage form needed to deliver the desired dose will of
course depend on the concentration of propranolol in
5. The composition as de?ned by claim 2 or 3,
the composition. The volume of solution or gel which
wherein
(i) is a systemically therapeutically effective
would be needed to deliver the typical dose of active
ingredient speci?ed above would be 0.1 to 0.5 ml of 20 unit ,B-adrenergic blocking amount of a nontoxic phar
maceutically acceptable salt of a compound having the
10% solution or gel‘.
formula
While the invention has been described in terms of
various preferred embodiments, the skilled artisan will
OH

appreciate that various modi?cations, substitutions,

25

CHZCHCHIZNHCH(CH3)2.

omissions and additions may be made without departing
from the spirit thereof. Accordingly, it is intended that
the scope of the present invention be limited solely be
the scope of the following claims.
30
What is claimed is:

ll. A pharmaceutically acceptable nasal composition,

6. The composition as de?ned by claim 5, wherein (i)
is a systemically therapeutically effective unit B-adren
ergic blocking amount of propranolol hydrochloride or
propranolol stearate.

in dosage unit form, for nasal administration to obtain a

systemic therapeutic ,B-adrenergic blocking response in
a warm-blooded animal, consisting essentially of, per
nasal dosage unit, (i) a systemically therapeutically ef

7. A pharmaceutically acceptable nasal composition,
in dosage unit form, for nasal administration to obtain a

fective unit B-adrenergic blocking amount of a com

systemic therapeutic ,B-adrcnergic blocking response in

pound having the formula

a warm-blooded animal, consisting essentially of, per
nasal dosage unit, (i) a systemically therapeutically ef
fective unit B-adrenergic blocking amount of proprano
lol stearate, and (ii) a nontoxic pharmaceutically accept

45

or a nontoxic pharmaceutically acceptable ester of salt ‘

thereof, and (ii) a nontoxic pharmaceutically acceptable
nasal carrier therefor, said composition being formu

able nasal carrier therefor.
8. The composition as de?ned by claim 7, said com
position comprising a nasal solution, a nasal suspension
a nasal ointment, a nasal gel, nasal drops or a nasal
spray.
9. The composition as de?ned by claim 7, said com

position comprising a nasal gel.
10. The composition as de?ned by claim 9, said com

position comprising a sustained release nasal gel.
111. Propranolol stearate.

lated as a nasal ointment or a nasal gel adapted for sus
tained release to the nasal mucosa.

ll!
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